John Taylor
Net worth: 1 M $ as of 30/07/2023
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ron Wooten | M | 64 |
Aceragen, Inc. (North Carolina)
 Aceragen, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Aceragen, Inc., Aceragen, Inc. is a biopharmaceutical company that develops therapeutics for orphan diseases. The company is based in Durham, NC. The company was founded in 2021 by John Clayton Taylor. Aceragen, Inc. (North Carolina) was acquired by Idera Pharmaceuticals, Inc. on September 28, 2022. | 3 years |
| Atul Chopra | M | - |
Aceragen, Inc. (North Carolina)
Aceragen, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Aceragen, Inc., Aceragen, Inc. is a biopharmaceutical company that develops therapeutics for orphan diseases. The company is based in Durham, NC. The company was founded in 2021 by John Clayton Taylor. Aceragen, Inc. (North Carolina) was acquired by Idera Pharmaceuticals, Inc. on September 28, 2022. | 3 years |
| Daniel Salain | M | 57 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Dougherty | M | 66 | 4 years | |
| Maxine Gowen | M | 66 | 7 years | |
| Roger Jeffs | M | 62 |
Spyryx Biosciences, Inc.
 Spyryx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Spyryx Biosciences, Inc. develops therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and chronic obstructive pulmonary disease. The company was founded by Robert Tarran in 2013 and is headquartered in Durham, NC. | - |
| James Geraghty | M | 69 | 10 years | |
| Cristina Csimma | M | 65 | 4 years | |
| Vin Milano Milano | M | 60 | 1 years | |
| Carl Kraus | M | - | 2 years | |
| Eric Lang | M | - |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
| Dale J. Christensen | M | - |
Spyryx Biosciences, Inc.
Spyryx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Spyryx Biosciences, Inc. develops therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and chronic obstructive pulmonary disease. The company was founded by Robert Tarran in 2013 and is headquartered in Durham, NC. | - |
| John J. Kirby | M | 52 | 1 years | |
| Bryant Lim | M | 53 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 14 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Taylor
- Personal Network